Study | Sample size (n) | Age (years) | Gender (M/F) | BMI (kg/m2) | PaO2/FiO2 at extubation | Comorbidity (n)a | Endpoints | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
Respiratory disease | Hypertension | Neurologic disease | Heart disease | Others | |||||||
HFNC group | 169 | 65 (19–88)* | 129/40 | 28.4 ± 5.3 | N/a | N/a | N/a | N/a | N/a | N/a | Primary outcome: oxygenation. Secondary outcomes: Atelectasis score, length of ICU and hospital stay, 28-day mortality, oxygenation indices, escalation of respiratory support, spirometry, comfort score. |
COT group | 171 | 66 (21–87)* | 129/42 | 29.2 ± 5.5 | N/a | N/a | N/a | N/a | N/a | N/a | |
Maggiore 2014 [12] | |||||||||||
HFNC group | 53 | 65 ± 18 | 33/20 | N/a | 239.4 ± 42.4 | 24 | N/a | N/a | 6 | 23 | Primary outcome: oxygenation. Secondary outcomes: oxygen desaturation, device displacement, requiring ventilator support#, reintubation, discomfort score. |
COT group | 52 | 64 ± 17 | 35/17 | N/a | 241.7 ± 51.1 | 24 | N/a | N/a | 5 | 23 | |
Corley 2015 [19] | |||||||||||
HFNC group | 81 | 63 ± 11.4 | 58/23 | 36 ± 5.2 | N/a | 26 | N/a | N/a | N/a | 5 | Primary outcome: Atelectasis score. Secondary outcomes: RR, oxygenation, subjective dyspnea, reintubation, failure of allocated treatment. |
COT group | 74 | 65 ± 11.1 | 56/18 | 35 ± 4.3 | N/a | 20 | N/a | N/a | N/a | 6 | |
Hernández 2016 [22] | |||||||||||
HFNC group | 264 | 51 ± 13.1 | 164/100 | < 30 | 227 ± 25 | 32 | 43 | 20 | 20 | 89 | Primary outcome: reintubation within 3 days. Secondary outcomes: mortality, multiorgan failure, postextubation respiratory failure, sepsis, respiratory infection, length of ICU and hospital stay, adverse events, time to reintubation. |
COT group | 263 | 51.8 ± 12.2 | 153/110 | < 30 | 237 ± 34 | 30 | 37 | 34 | 23 | 79 | |
Futier 2016 [27] | |||||||||||
HFNC group | 108 | 62 ± 12 | 61/47 | 25 ± 4 | N/a | 10 | 34 | N/a | N/a | 76 | Primary outcome: rate of hypoxemia 1 h after extubation. Secondary outcomes: pulmonary complications, length of ICU and hospital stay, in-hospital mortality. |
COT group | 112 | 61 ± 13 | 64/48 | 25 ± 4 | N/a | 8 | 35 | N/a | N/a | 67 | |
Song 2017 [18] | |||||||||||
HFNC group | 30 | 66 ± 14 | 16/14 | N/a | 207 ± 27.5 | 19 | N/a | N/a | 7 | 4 | Primary outcome: therapy success rate. Secondary outcomes: RR, HR, oxygenation indices, MAP. |
COT group | 30 | 71 ± 13 | 18/12 | N/a | 204 ± 29 | 19 | N/a | N/a | 7 | 4 | |
Fernandez 2017 [23] | |||||||||||
HFNC group | 78 | 67.3 ± 12 | 46/32 | N/a | N/a | 22 | N/a | N/a | 9 | N/a | Primary outcome: respiratory failure within 3 days. Secondary outcomes: length of ICU and hospital stay, reintubation, mortality. |
COT group | 77 | 69.7 ± 13 | 55/22 | N/a | N/a | 24 | N/a | N/a | 9 | N/a | |
Tiruvoipati 2010 [25] | |||||||||||
HFNC group | 42 | 65.22 ± 17.6 | 20/22 | N/a | > 175 | N/a | N/a | N/a | N/a | N/a | Primary outcome: efficacy of oxygenation. Secondary outcomes: HR, RR, blood pressure, comfort score, tolerance score. |
COT group | 42 | 65.22 ± 17.6 | 20/22 | N/a | > 175 | N/a | N/a | N/a | N/a | N/a | |
Rittayamai 2014 [13] | |||||||||||
HFNC group | 17 | 66.8 ± 13.8 | 10/7 | N/a | ≥ 150 | 9 | 8 | N/a | 8 | N/a | Primary outcome: dyspnea score. Secondary outcomes: HR, RR, MAP, comfort score. |
COT group | 17 | 66.8 ± 13.8 | 10/7 | N/a | ≥ 150 | 9 | 8 | N/a | 8 | N/a | |
Di mussi 2018 [26] | |||||||||||
HFNC group | 14 | 71.5 ± 9 | 12/2 | N/a | > 150 | N/a | N/a | N/a | N/a | N/a | Primary outcome: neuroventilatory drive and work of breathing. Secondary outcomes: RR, oxygenation indices. |
COT group | 14 | 71.5 ± 9 | 12/2 | N/a | > 150 | N/a | N/a | N/a | N/a | N/a |